Quick Answer
PROKIDNEY CORP. reported Net Income of -$68.99 million for fiscal year 2025.
PROKIDNEY CORP. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$68.99M -12.7% |
-$61.19M -72.5% |
-$35.47M | — | -$55.15M | — |
| Diluted EPS | — | — | — | -$0.23 | — | — |
| Total Assets | $335.57M -23.9% |
$441.07M +4.9% |
$420.55M -18.8% |
$518.00M +1185.4% |
$40.30M | — |
| Cash and Equivalents | $108.54M +9.5% |
$99.12M +63.4% |
$60.65M -87.6% |
$490.25M +2284.7% |
$20.56M | — |
| Stockholders Equity | -$1.01B -1.6% |
-$994.95M +9.8% |
-$1.10B -0.6% |
-$1.10B | $0.00 -100.0% |
$9.86M -37.9% |
| R&D Expense | $114.12M -10.6% |
$127.67M +19.6% |
$106.71M +30.0% |
$82.07M +77.4% |
$46.26M +119.8% |
$21.04M |
| Operating Income | -$165.01M +10.2% |
-$183.68M -21.2% |
-$151.52M +1.0% |
-$153.01M -177.6% |
-$55.11M -103.9% |
-$27.02M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$16.47M | +8.0% | +0.5% |
| Total Assets | September 30, 2025 | $351.61M | -25.9% | -5.5% |
| Cash and Equivalents | September 30, 2025 | $95.32M | -11.8% | +12.2% |
| Stockholders Equity | September 30, 2025 | -$1.01B | -2.9% | -0.6% |
| R&D Expense | September 30, 2025 | $26.82M | -14.2% | +3.6% |
| Operating Income | September 30, 2025 | -$38.54M | +21.3% | +2.9% |
- PROKIDNEY CORP. reported Net Income of -$68.99 million for fiscal year 2025.
- PROKIDNEY CORP. showed a decrease of -12.7% in Net Income compared to the prior fiscal year.
- PROKIDNEY CORP. reported Diluted EPS of $0.23 per share (loss) for fiscal year 2022.
- PROKIDNEY CORP. reported Total Assets of $335.57 million for fiscal year 2025.
- PROKIDNEY CORP. showed a decrease of -23.9% in Total Assets compared to the prior fiscal year.
- PROKIDNEY CORP. reported Cash and Equivalents of $108.54 million for fiscal year 2025.
- PROKIDNEY CORP. showed an increase of +9.5% in Cash and Equivalents compared to the prior fiscal year.
- PROKIDNEY CORP. reported Stockholders Equity of -$1.01 billion for fiscal year 2025.
- PROKIDNEY CORP. showed a decrease of -1.6% in Stockholders Equity compared to the prior fiscal year.
- PROKIDNEY CORP. reported R&D Expense of $114.12 million for fiscal year 2025.
- PROKIDNEY CORP. showed a decrease of -10.6% in R&D Expense compared to the prior fiscal year.
- PROKIDNEY CORP. reported Operating Income of -$165.01 million for fiscal year 2025.
- PROKIDNEY CORP. showed an increase of +10.2% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: